Mammoth Biosciences uses CRISPR/Cas9 technology to detect diseases. The company was founded in 2017 by Janice Chen, Jennifer Doudna, Trevor Martin, and Lucas Harrington.
This gene editing (CRISPR) company was founded by Feng Zhang, and David R. Liu, among others. Their research focuses on engineering targeted and durable gene-edited medicines using the CRISPR Cas9 and Cas12a (Cpf1) nuclease to target a wide range of genetic changes.